Announced today that the American Society of Clinical Oncology decided to reverse its decision and to ...
Presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions ...
Announced that CEO Dr. Fahar Merchant, President and CEO will present and participate in one-on-one ...
Announced today that two posters will be presented at the American Association for Cancer Research Annual ...
Today announced the first patient dosed in the combination arm of the Phase 1/2 ABILITY (ABeta-only ...
Today announced initiation of enrollment in the combination arm of the Phase 1/2 ABILITY (ABeta-only ...
Announced that a poster presentation and an oral summary highlighting longer term follow up results ...
Received a Staff Delisting Determination from the Listing Qualifications Department of the NASDAQ Stock ...
Today announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the ...
Announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development ...